I'll confess I've only ever passed through CT and have no

New Post Public Reply Private Reply Replies (1) Message Board
JLang CTMedic #102178
467
I'll confess I've only ever passed through CT and have no experience with your states certification process, but if there's requirements for structural biology, immunology, virology, and cell bio these days, kudos.. you still have a drastically less than complete grasp of what you're writing, and this is the last time I'm bothering pointing that out.

Mutation rate isn't moot, it's baseline.. this is about Variants of Concern vs previous variants they're outclassing. For the nth time. They all have roughly the same mutation rate regardless of host.. it's non-relevant with respect to this comparison, not irrelevant in general. You don't comprehend this.

Again, immune evasion is not the only or I'd argue even the primary selective force for a novel virus.. binding affinity and transmission are of higher relative importance. The strength of the host immune system does matter: in that weaker ones allow the pathogen more time to become familiar and increase binding affinity to the pathogens receptors of choice. This is elementary. You don't comprehend this.

A strong, functional host doesn't allow the pathogen the luxury of time to increase binding affinity, as evidenced by the multitude of papers describing weeks-months long, active covid infections in the immunocompromised, with several advantage conferring mutations, with sequential viral samples/references exquisitely building the roadmap of these accumulated mutations... And literally zero of the same detailing a similar process in hosts that have a disease course that lasts for days, max. I've posted several, read them on repeat until it sinks in.

200M cases does provide ample grounds for mutations. Those that are in immunocompromised hosts do even more.

No, it's an incomplete analogy, because fighting isn't the only thing the virus is doing. It's travelling, picking a lock, and fucking as well. If it fails on any of those fronts, it doesn't reproduce. The immunocompromised allow for mutations in the most crucial of those factors.. for a Novel Virus.. binding affinity to a new species receptor.

The non-compromised hosts don't have "healthier locks".. they have roughly the same ACE2 receptors as the immunocompromised. The virus has less time trying to pick at ACE2 in a healthy host. Less mutations.. even you can't argue this. And what you don't understand is, this process is iterative and *greater at driving the increase in binding affinity of the viral spike protein and ACE2 in compromised hosts*. The exact opposite of what you're suggesting.

I'm out of ways to explain this.. these are rudimentary concepts, well illustrated in the literature. Again, your issues are yours to bear from here on out.










CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 307

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 211

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 246

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 694

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 63

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 351

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 239

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 105

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 27

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 180

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading

Top 5 Most Recently Viewed Articles

HD Hyundai Sparks Fusion Hopes with ITER Milestone

Updated Category News Views 9

Hold on to Your Hard Hats, Fusion Milestone Achieved Look who's making waves in the world of nuclear fusion. HD Hyundai Heavy Industries has hit a crucial benchmark in the ITER nuclear fusion project. This ain't your run-of-the-mill accomplishment, folks. We're talking about completing the assembly of some of the most complex and intricately designed machinery known to...

Continue Reading
ChemoMetec Boosts Financial Outlook with Anticipated Growth

Updated Category News Views 353

ChemoMetec Boosts Financial Outlook Amid Growing Interest ChemoMetec is excited to announce an upgrade in its financial guidance as the company sees a growing demand for its pioneering technologies, particularly the highly regarded XcytoMatic platform. This surge in interest bodes well for the company's revenue and profit, reflecting a positive trajectory as it approaches...

Continue Reading
GDS Holdings Completes Successful C-REIT IPO on Shanghai Exchange

Updated Category News Views 200

GDS Holdings Limited Celebrates C-REIT IPO Success GDS Holdings Limited, known as GDS, is thrilled to announce that it has successfully completed its initial public offering of its China REIT, or C-REIT, on the Shanghai Stock Exchange. This milestone marks an exciting moment for the company and its stakeholders as market interest surpassed expectations. Highlighting the...

Continue Reading
Innovative E-Waste Solutions from Techbros Redefine Recycling

Updated Category News Views 273

AI-Driven E-Waste Innovation from Techbros In a remarkable leap towards sustainability and innovative technology, Techbros Electronic Recycling proudly announces the launch of the Southwest's first fully integrated AI-driven IT asset disposition (ITAD) and e-waste processing facility. This state-of-the-art facility exemplifies the future of electronics recycling by...

Continue Reading
SageSure Welcomes Insurance Veteran Peter Hearn to Board

Updated Category News Views 268

SageSure Welcomes New Board Member SageSure, one of the largest managing general underwriters that focus on markets exposed to catastrophe risks, has taken a significant step by appointing Peter Hearn to its Board of Managers. This strategic move is anticipated to bolster the company’s leadership and industry insights. Peter Hearn's Impressive Background Peter Hearn...

Continue Reading